Veracyte (VCYT) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Veracyte (VCYT) right now is Decipher prostate franchise: Decipher is the largest and fastest-growing revenue line, up roughly 30% year over year in Q1 2026 to about $87M in testing revenue. Revenue (TTM) is ~$517M. If that keeps playing out, the setup is favourable; the risk to it is revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. No one can predict where VCYT trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Veracyte (VCYT) higher?
1. Decipher prostate franchise
Decipher is the largest and fastest-growing revenue line, up roughly 30% year over year in Q1 2026 to about $87M in testing revenue. Expanding clinical guideline inclusion and use across more stages of prostate cancer support continued double-digit volume growth.
2. Afirma thyroid dominance
Afirma is used by a large share of US endocrinologists and is close to synonymous with thyroid nodule assessment. It grew about 21% in Q1 2026, and add-on features like the Xpression Atlas extend it toward therapy-selection use cases.
3. Sustained profitability and cash generation
Veracyte has shifted from cash-burning to consistently profitable, with adjusted EBITDA margins near 30% and rising full-year guidance. That self-funding profile lets it invest in new tests and studies without diluting shareholders heavily.
4. Pipeline and new test expansion
The company is investing in new assays (including tissue and blood-based tests) and expanding Decipher and Afirma indications. New-test contributions are framed as upside on top of the mid-teens core testing growth.
What could weigh on VCYT?
Revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. The stock trades at a premium valuation (P/E in the mid-40s), which amplifies downside if growth decelerates or guidance is missed. Medicare and commercial payer decisions drive a large portion of realized revenue, making pricing and coverage a persistent uncertainty. Larger diagnostics rivals such as Exact Sciences, Guardant Health, and Natera have deeper resources and are expanding into overlapping oncology testing areas. New-test launches and international expansion carry execution and regulatory risk.
Where VCYT trades today
A forecast starts from where the stock actually is. These are VCYT's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for VCYT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a VCYT forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the VCYT guide and whether VCYT is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the VCYT outlook
The bottom line: what is driving Veracyte (VCYT) is Decipher prostate franchise, with revenue (ttm) at ~$517M. If that keeps playing out the setup is favourable; the risk is revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. No one can predict the price, so treat any VCYT forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
More on VCYT
- VCYT stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- Is VCYT a buy? (the case for, the risks, and a framework to decide)
- Does VCYT pay a dividend?
Build a basket around VCYT with Walnut
Use Veracyte as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Veracyte (VCYT)?
+
No one can reliably predict where VCYT will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Veracyte higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive VCYT higher?
+
The main growth drivers are Decipher prostate franchise; Afirma thyroid dominance; Sustained profitability and cash generation. Whether they play out is the real question, not a guaranteed path.
What are the risks to VCYT?
+
Revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. The stock trades at a premium valuation (P/E in the mid-40s), which amplifies downside if growth decelerates or guidance is missed. Medicare and commercial payer decisions drive a large portion of realized revenue, making pricing and coverage a persistent uncertainty. Larger diagnostics rivals such as Exact Sciences, Guardant Health, and Natera have deeper resources and are expanding into overlapping oncology testing areas. New-test launches and international expansion carry execution and regulatory risk.
Will VCYT stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Veracyte's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is VCYT a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the VCYT "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is Veracyte growing?
+
Q1 2026 revenue rose about 21% year over year to roughly $139M, with Decipher up around 30% and Afirma up around 21%. Full-year 2026 guidance implies continued double-digit growth.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.